Welcome to our dedicated page for Q32 Bio SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen report beneficial ownership of 1,173,396 shares of Q32 Bio Inc. common stock as of June 30, 2026. This represents 4.95% of 23,681,415 Q32 Bio shares outstanding, including shares issued in a May 26, 2026 private placement.
The reporting persons have no sole voting or dispositive power and instead report shared voting and shared dispositive power over all 1,173,396 shares through an investment fund managed by Point72 Asset Management. They state the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.
Q32 Bio Inc. received an amended Schedule 13G indicating that Sirenia Capital Management LP and Alex Silverstein no longer beneficially own any of the company’s common stock. The filing reports 0 shares beneficially owned, representing 0% of the outstanding common stock, with no sole or shared voting or dispositive power.
Sirenia had previously reported holdings on behalf of investment funds it manages, with Mr. Silverstein as managing member of Sirenia’s general partner. Both parties now report ownership of 5 percent or less of this class.
Q32 Bio Inc. is a clinical stage biotechnology company developing bempikibart, a fully human anti‑IL‑7Rα antibody, for alopecia areata and other autoimmune and inflammatory diseases. It has no approved products and continues to invest heavily in research and development.
For the quarter ended June 30, 2026, the company reported a net loss of $8.9 million, or $0.44 per share, compared with $9.5 million, or $0.78 per share, a year earlier. For the first six months of 2026, the net loss was $16.6 million versus $20.5 million in the prior‑year period.
Cash and cash equivalents were $106.3 million at June 30, 2026, up from $48.3 million at year‑end 2025, driven by a registered direct offering, at‑the‑market sales and a private placement, while venture debt was fully repaid. Subsequent to quarter‑end, a follow‑on public offering added $187.6 million of net proceeds, further strengthening liquidity. Management expects existing cash to fund operations for at least one year, though additional capital will ultimately be required.
Q32 Bio Inc. reported second-quarter 2026 results and progress in its alopecia areata program. In Part B of the Phase 2a SIGNAL-AA trial, bempikibart achieved a 35.3% mean reduction in Severity of Alopecia Tool score in the modified intent-to-treat set; 40.0% of patients reached a SALT-20 response at Week 36 in that set and 30.3% in the full intent-to-treat population, with a generally well-tolerated safety profile. Enrollment and dosing continue in the open-label extension, and a registration-directed program in severe and very severe alopecia areata is planned for the first half of 2027, subject to regulatory discussions in late 2026.
Cash and cash equivalents were $106.3 million as of June 30, 2026, and a July 2026 public offering raised approximately $200.0 million in gross proceeds, which together are expected to fund operations through topline Phase 3 results for the planned registration-directed program. For the quarter, research and development expenses were $4.3 million, general and administrative expenses $4.9 million, and net loss $8.9 million, or $0.44 per share.
Q32 Bio Inc. is reported to have 931,000 shares of its Common Stock, par value $0.0001 per share, beneficially owned by Opaleye, L.P., Opaleye Management Inc., and James Silverman (collectively the reporting persons). Based on 16,956,415 shares of Common Stock outstanding as of May 1, 2026, this represents 5.49% of the class.
The Fund directly holds the 931,000 shares, while Opaleye Management Inc., as investment adviser to the Fund, and James Silverman, as the controlling person of the adviser, may be deemed to share voting and dispositive power over these shares. The reporting persons disclaim that this filing constitutes an admission of beneficial ownership for purposes of Section 13 of the Securities Exchange Act of 1934 or otherwise.
Q32 Bio Inc. is registering the resale of up to 6,875,000 shares of common stock by existing investors under a shelf prospectus. This includes 6,725,000 shares already outstanding and 150,000 shares issuable upon exercise of pre-funded warrants issued in a May 26, 2026 private placement.
The company is not selling shares in this offering and will receive no proceeds from resale, though it may receive nominal cash if pre-funded warrants are exercised. Q32 Bio is a clinical-stage biotech focused on bempikibart for alopecia areata and related autoimmune conditions. It previously restructured to prioritize bempikibart and sold ADX-097 rights to Akebia Therapeutics. The stock trades on Nasdaq as “QTTB” and closed at $15.21 on July 27, 2026, with 29,763,999 shares outstanding as of July 16, 2026.
Q32 Bio Inc. director Arthur Tzianabos reported a corrected grant of 10,826 stock options to acquire Common Stock, awarded on June 12, 2026 at an exercise price of $12.64 per share and expiring on June 11, 2036. The options vest and become exercisable in full on the earlier of June 12, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. This amendment updates a Form 4 filed on June 16, 2026 solely to correct the number of options awarded.
Q32 Bio Inc. director Sven Ante Lundberg reported a grant of 10,826 stock options on June 12, 2026 at an exercise price of $12.64 per share, expiring June 11, 2036. The options vest in full upon the earlier of June 12, 2027 or the next annual stockholders’ meeting, and this Form 4/A corrects the number of options originally reported.
Q32 Bio Inc. director Kathleen LaPorte received a grant of 10,826 stock options on June 12, 2026 at an exercise price of $12.64 per share, expiring June 11, 2036. This amendment corrects the previously reported grant size. The options vest in full on the earlier of June 12, 2027 or the next annual meeting of stockholders, subject to her continued service.